momelotinib

Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells.

Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.

Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.

Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.

[N-(Cyanomethyl)-4-(2-((4-(3-oxo-4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide-d4] is the deuterium-labeled form of [N-(Cyanomethyl)-4-(2-((4-(3-oxo-4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide].

FC11409B is a CAIX inhibitor, inhibiting breast cancer invasion and metastasis.